3 March 2021, 19:00 - 20:00
Many scientists are hoping that personalised medicine is the future. This approach will ensure that the patient is at the centre of the healthcare system. However, when researchers develop treatment options in the laboratory, there is a focus on studies in male species. Our gender has a huge impact on whether we will get certain diseases, what type of symptoms we will have when we are ill, and how effective certain treatments will be in improving our health. This session will discuss these matters in closer detail and consider the way research is moving to ensure that our gender does not define our medicine.
Dr Havovi Chichger, Senior Lecturer in Biomedical Science, ARU, discusses how gender relates to her research, which focuses on a range of cardiovascular diseases, from lung infection to diabetes, and how we can find treatment options for patients with these diseases. In particular, she is interested in how our blood vessels function in these diseases and how, if we can improve the condition of our vasculature, we can improve the health of patients. Through these studies, she has been fascinated by how we, as researchers, study these diseases and what we can do to ensure the best possible experiments are performed to evaluate efficacy of treatment for all patients.
In 2011, Havovi earned her doctorate in physiology from University College London, which focused on studying the role of renal and small intestinal glucose transport in metabolic syndrome and diabetes. As a postdoctoral fellow at Brown University, Havovi's research developed into vascular dysfunction in settings of disease including lung disease.
Since joining ARU in 2015, Havovi has developed a leading research team focused on understanding how blood vessels function and how they are disrupted by diseases such as diabetes and lung injury, with the aim of developing new therapies to improve patient health.
Event presented as part of ARU's programme of events to celebrate International Women's Day.